December 23, 2021
CYTOCON DB and CYTOCON DB Open are updated!
CYTOCON DB is a database of human baseline concentrations of cytokines and cells measured in different tissues. CYTOCON DB Open is a version of the database designed for public use. It has the same functionality as CYTOCON DB, however, it is updated once per year.
In 2021 CYTOCON DB Open was extended with new data: 135 diseases, 109 tissues, 125 molecules, 43 cells and 22305 concentrations were introduced. For this purpose 476 articles were reviewed.
As for CYTOCON DB, its latest version 1.3.8.22 contains approximately 35000 concentrations and 1000 articles were reviewed for these purpose!
Recent update result - in unit %__T-cells_;CD8+_Blood_COVID-19 - average concentration of CD8+ T-cells was changed from 207933 to 214081 kcells/L (averaged from 135 concentrations from articles annotated to the DB)
In unit %__T-cells_;CD4+_Blood_COVID-19 - average concentration of CD4+ T-cells was changed from 345548 to 353710 kcells/L (averaged from 166 concentrations from articles annotated to the DB)
For more details, please visit: https://cytocon.insysbio.com/
To experience CYTOCON DB Open visit: https://www.cytocon-open.insysbio.com/
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | February 2021 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
|
15
1.
15 Feb 2021 15:19
InSysBio to be interviewed in frames of INNOVATORS VS COVID-19 series
[Moscow – 15.02.2021] Oleg Demin Jr, Head of Oncology and Immuno-Oncology at InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, has talked to startup.info, a global innovation ecosystem magazine. The interview in frames of the series "INNOVATORS VS COVID-19" covers the application of system-pharmacology modeling to different stages of drug research and development and InSysBio's current development in the context of the pandemic.
|
16
|
17
|
18
|
19
|
20
|
21
|
|
22
|
23
|
24
|
25
|
26
|
27
|
28
|
Thank you for your message! We will get back to you shortly.
